Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02580708
Title A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Clovis Oncology, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
Tennessee Oncology, PLLC - The Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field